CDD-1653

• Description:

  CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM) . CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway[1].

• UNSPSC:

  12352005

• Target:

  TGF-β Receptor

• Type:

  Reference compound

• Related Pathways:

  TGF-beta/Smad

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Others

• Assay Protocol:

  https://www.medchemexpress.com/cdd-1653.html

• Concentration:

  10mM

• Purity:

  99.38

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1N(CCN(C1)C2=NC(NC3=CC=CC(S(=O)(N)=O)=C3)=NC=C2OC)C4=CC=CC=C4

• Molecular Formula:

  C21H22N6O4S

• Molecular Weight:

  454.50

• References & Citations:

  [1]Modukuri R K, et al. Discovery of highly potent and BMPR2-selective kinase inhibitors using DNA-encoded chemical library screening[J]. Journal of Medicinal Chemistry, 2023, 66 (3) : 2143-2160.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [3034216-44-6]